Screen diabetics and hypertensive patients regularly and use modern therapies

High blood pressure and diabetes are the main causes of CKD – early diagnosis and treatment can reduce the risk of kidney failure and cardiorenal complications. Regular screening of these high-risk patients is therefore crucial. This is because the options for inhibiting progression with medication have improved considerably in recent years. In Switzerland, three SGLT-2-i are currently available for progression inhibition in CKD, two of which are also available for non-diabetics. And while finerenone (nsMRA) has been approved for type 2 diabetics with CKD for some time, this now also applies to a semaglutide preparation (GLP-1-RA).